Rolipram

Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

Product Specifications

CAS Number

[61413-54-5]

Product Name Alternative

(R, S) -Rolipram; (±) -Rolipram; ZK 62711

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; HIV; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Rolipram.html

Purity

99.45

Solubility

DMSO : ≥ 41 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NCC(C2=CC=C(OC)C(OC3CCCC3)=C2)C1

Molecular Formula

C16H21NO3

Molecular Weight

275.35

Precautions

H302, H315, H319, H335

References & Citations

[1]MacKenzie SJ, et al. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocyticcells. Biochem J. 2000 Apr|[2]Korhonen R, et al. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. Br J Pharmacol. 2013 Aug;169 (7) :1525-36.|[3]Shalaby AM, et al. Effect of rolipram, a phosphodiesterase enzyme type-4 inhibitor, on γ-amino butyric acid content of the frontal cortex in mice exposed to chronic mild stress. J Pharmacol Pharmacother. 2012 Apr;3 (2) :132-7.